UCLA researchers developed a non-invasive imaging method using 89Zr-TLX250 to detect clear-cell renal cell carcinoma. This ...

A recent study conducted by UCLA Health Jonsson Comprehensive Cancer Center researchers found that new, non-invasive imaging ...

A recent study conducted by UCLA Health Jonsson Comprehensive Cancer Center researchers found that new, non-invasive imaging ...

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic ...

Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 ...

No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.

The following is a summary of “Frailty and Renal Cell Carcinoma: Integration of Comprehensive Geriatric Assessment into ...

The healthcare brand offers paid research opportunities for patients and family caregivers in the USNew Hope, Pennsylvania--(Newsfile Corp. - ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...